Table 1 Baseline characteristics according to the presence of Achilles enthesitis
Total N = 749 | Current Achilles enthesitis N = 46 | No current Achilles enthesitis N = 703 | p-value | |
|---|---|---|---|---|
Sex (male) | 564 (75.3%) | 32 (69.6%) | 532 (75.7%) | 0.352 |
Age, mean (SD) | 48.4 (12.3%) | 47.8 (10.9) | 48.4 (12.4) | 0.759 |
BMI, mean (SD) | 26.7 (4.3) | 27.7 (4.9) | 26.6 (4.2) | 0.412 |
University studies | 91/667 (13.6%) | 5/45 (11.1%) | 86/622 (13.8%) | 0.608 |
Single | 109/667 (16.3%) | 7/45 (15.6%) | 102/622 (16.4%) | 0.883 |
Smoking (ever) | 267/691 (53.1%) | 17/41 (41.5%) | 350/650 (53.8%) | 0.123 |
Age of onset, mean (SD) | 27.1 (10.3) | 27.3 (13.2) | 27.0 (10.1) | 0.709 |
Disease duration, mean (SD) | 21.4 (12.7) | 20.5 (12.0) | 21.5 (12.8) | 0.726 |
Diagnosis delay, mean (SD) | 8.1 (9.5) | 7.6 (8.6) | 8.1 (9.6) | 0.786 |
Family history of SpA | 420/701 (59.9%) | 28/40 (70.0%) | 392/661 (59.3%) | 0.180 |
HLA-B27 positive | 586/721 (81.3%) | 37 (80.4%) | 549/675 (81.3%) | 0.880 |
Synovitis (ever) | 250/748 (33.4%) | 21 (45.7%) | 229/702 (32.6%) | 0.070 |
Psoriasis | 82/746 (11.0%) | 7 (15.2%) | 75/700 (10.7%) | 0.344 |
Inflammatory bowel disease | 45 (6.0%) | 2 (4.3%) | 43 (6.1%) | 1.000 |
Dactylitis | 55/745 (7.4%) | 6 (13.0%) | 49/699 (7.0%) | 0.141 |
Uveitis | 154/745 (20.7%) | 8 (17.4%) | 146/699 (20.9%) | 0.571 |
Swollen joints, mean (SD) | 0.3 (1.6) | 0.8 (1.7) | 0.3 (1.6) | < 0.001 |
MASES score, mean (SD) | 2.2 (1.9) | 2.5 (1.9) | 2.1 (1.9) | 0.115 |
csDMARDs (ever) | 155/742 (20.9%) | 27/45 (37.8%) | 138/697 (19.8%) | 0.004 |
csDMARDs (current) | 159/746 (21.3%) | 18 (39.1%) | 141/700 (20.1%) | 0.002 |
Anti-TNF (ever) | 261 (34.8%) | 19 (41.3%) | 242 (34.4%) | 0.343 |
Anti-TNF (current) | 157 (21.0%) | 10 (21.7%) | 147 (20.9%) | 0.894 |
CRP mg/L, mean (SD) | 9.2 (13.3) | 11.0 (14.1) | 9.1 (13.2) | 0.870 |
ASDAS-CRP, mean (SD) | 2.7 (1.1) | 3.1 (1.2) | 2.7 (1.0) | 0.014 |
ASDAS low disease activity | 206/681 (30.2%) | 7/40 (17.5%) | 199/641 (31.0%) | 0.070 |
ASDAS inactive disease | 66/681 (9.7%) | 3/40 (7.5%) | 63/641 (9.8%) | 0.788 |
Global VAS (0–10), mean (SD) | 4.6 (2.7) | 5.9 (2.6) | 4.6 (2.7) | 0.001 |
BASDAI (0–10), mean (SD) | 4.2 (2.4) | 5.6 (2.2) | 4.1 (2.3) | < 0.001 |
mBASDAI (0–10), mean (SD) | 4.7 (2.5) | 5.7 (2.3) | 4.7 (2.5) | 0.007 |
BASFI (0–100), mean (SD) | 38.8 (27.3) | 47.3 (27.6) | 38.2 (27.2) | 0.031 |
PC-SF12, mean (SD) | 34.5 (11.6) | 31.4 (11.8) | 34.7 (11.6) | 0.018 |
MC-SF12, mean (SD) | 47.2 (13.8) | 46.2 (15.3) | 47.3 (13.7) | 0.748 |
Total BASRI, mean (SD) | 8.0 (4.0) | 6.1 (3.0) | 7.3 (4.01) | 0.068 |